CRL Charles River Laboratories International, Inc. Common Stock

NYSE · Life Sciences Tools & Services · SEC EDGAR에서 보기 ↗
$290.01
가격 · 8월 19, 2026
기준 재무 정보 8월 5, 2026

Charles River Laboratories International, Inc. Common Stock 정보 위키백과 회사 개요

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.

더 보기

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.

Charles River Laboratories is considered one of the largest CROs globally, known for its role in toxicology studies, animal research models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration (FDA). The company has also been the subject of public scrutiny and regulatory attention over its use of laboratory animals, including dogs, primates, and horseshoe crabs.

As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL.

History

Charles River was founded in 1947 by Henry Foster, a young veterinarian who purchased one thousand rat cages from a Virginia farm and set up a one-person laboratory in Boston overlooking the Charles River. He supplied local researchers with laboratory animals.

In 1955, the company's headquarters were relocated to their current home in Wilmington, Massachusetts. The organization became an international entity in 1966 by opening a new animal production facility in France.

The first commercial, comprehensive genetic monitoring program was implemented by Charles River in 1981. Three years later, they were acquired by Bausch & Lomb. In 1988, the organization began creating transgenic mice and rats. In the 1990s, they began in vitro endotoxin testing. In the 1990s, Jim Foster bought Charles River back from Bausch & Lomb, and the company later went public on the New York Stock Exchange.

Charles River launched the Humane Care Imperative in 2002, designed to raise awareness and train employees on animal welfare's importance. The same year, they were named "Company of the Year" by The Boston Globe. The company introduced preconditioning services in 2005 to provide customers with study-ready animals.

In 2008, Charles River signed a ten-year contract to partner with the National Cancer Institute and opened a facility in Frederick, Maryland.

In April 2019, Charles River announced it would cease its San Diego operations, moving the breeding of rodents for testing compounds to Hollister, California.

In March 2023, the Born Free USA animal welfare organization protested against Charles River's plan to export 1,000 endangered juvenile long-tail macaques to Cambodia for testing.

Acquisitions

In 1988, Charles River purchased Specific Pathogen Antigen Free Avian Services (SPAFAS) and serologic diagnostic services Merck, Sharp, and Dohme.

Between 1996 and 2000, the company acquired Endosafe, Inc. and Sierra Biomedical.

In October 2003, Charles River Laboratories merged with Inveresk, a research company based in the United Kingdom. The company was known then as Charles River Laboratories. Inveresk specialised in clinical research and pre-clinical testing, and their main facilities are in Edinburgh, Scotland. In late 2009, Charles River sold its Clinical Services Division in Edinburgh to Quotient Bioresearch.

In 2010, Charles River Laboratories attempted to acquire WuXi PharmaTech, a China-based contract research organization, but the offer was withdrawn when the deal faced opposition from several large Charles River investors, including Relational Investors, JANA Partners, and Neuberger Berman. The proxy advisory firm RiskMetrics had also recommended that Charles River's shareholders vote against the proposed deal.

From 2008 to 2013, Charles River acquires several companies including NewLab Bioquality AG, MIR Preclinical Services, Piedmont Research Center, LLC, Cerebricon, Ltd., Accugenix, and Vital River, allowing the company to expand their research models and services portfolio to drug development and discovery markets in China.

The acquisitions of Argenta and BioFocus in 2014 allowed Charles River to establish itself as a full-service, early-stage contract research organization with integrated in vitro and in vivo capabilities from target discovery through pre-clinical development.

In July 2015, the company announced it would acquire Celsis International for $212 million.

In 2016, the company announced it was set to acquire WIL Research for approximately $585 million in cash and Blue Stream Laboratories.

In August 2017, the business announced it would acquire Brains On-Line.

In January 2018, the company announced it would acquire KWS BioTest for up to £18 million ($24.4 million). In February of the same year, Charles River announced it would acquire MPI Research for approximately $800 million in cash. The transaction was completed on April 3, 2018.

In February 2019, the company announced it would acquire Citoxlab for €448 million in cash (approximately $500 million), including the former acquisitions of the French company, AccelLAB, Atlanbio and Solvo Biotechnology. The transaction was completed on April 29. In December of the same year the business announced it would acquire HemaCare for approximately $380 million in cash.

In August 2020, the company announced it would acquire Cellero for $38 million in cash.

In January 2021, the company announced it would acquire Distributed Bio, Inc., an antibody discovery business.

In February 2021, Charles River announced it would acquire Cognate BioServices, Inc. for $875 million.

In March 2021, Charles River announced the acquisition of Retrogenix for $48 million.

In May 2021, Charles River announced the acquisition of Vigene Biosciences, a gene therapy contract development and manufacturing organization (CDMO), for $292.5 million.

In October 2021, a Japanese subsidiary of Charles River was acquired by Jackson Laboratory for $63M USD.

In April 2022, the company announced it would acquire Explora BioLabs.

In January 2023, the business announced it would acquire SAMDI Tech, Inc.

출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗

Wikidata ↗

CRL 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위

가격
$290.00
시가총액
$14.27B
P/E (TTM)
-99.7
EPS (TTM)
$-2.91
매출 (TTM)
$4.02B
배당 수익률
ROE
-4.4%
부채/자본
0.0
52주 범위
$144 – $291

CRL 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의

10년 성과 매출, 순이익, 마진 및 EPS 추세

매출 및 순이익 $4.02B
10-point trend, +138.8%
2016-12-31 2025-12-27
EPS $-2.91
10-point trend, -190.1%
2016-12-31 2025-12-27
잉여현금흐름 $518M
10-point trend, +111.6%
2016-12-31 2025-12-27
마진 -3.6%

가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?

지표
5년 추세
CRL
동종업계 중앙값
P/E (TTM)
5-point trend, -244.1%
-99.7
39.9
P/S (TTM)
5-point trend, -52.6%
3.6
5.6
P/B
5-point trend, -56.9%
4.5
4.1
EV / EBITDA
5-point trend, +6.5%
32.8
Price / FCF (주가 / FCF)
5-point trend, -44.8%
27.5

수익성 총, 영업 및 순이익률; ROE, ROA, ROIC

지표
5년 추세
CRL
동종업계 중앙값
Operating Margin (영업이익률)
5-point trend, -96.2%
0.63%
Net Profit Margin (순이익률)
5-point trend, -132.5%
-3.6%
11.7%
ROA
5-point trend, -131.5%
-2.0%
4.7%
ROE
5-point trend, -125.9%
-4.4%
8.5%
ROIC
5-point trend, -94.1%
1.1%

재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성

지표
5년 추세
CRL
동종업계 중앙값
Debt / Equity (부채 / 자기자본 비율)
5-point trend, +0.00
0.0
15.3
Current Ratio (유동비율)
5-point trend, +4.7%
1.3
1.7
Quick Ratio (당좌 비율)
5-point trend, -3.9%
0.8

성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR

지표
5년 추세
CRL
동종업계 중앙값
Revenue YoY (매출 YoY)
5-point trend, +13.4%
-0.85%
Revenue CAGR 3Y (매출 CAGR 3년)
5-point trend, +13.4%
0.33%
Revenue CAGR 5Y (매출 CAGR 5년)
5-point trend, +13.4%
6.6%
EPS YoY
5-point trend, -138.3%
-97.8%
Net Income YoY (순이익 YoY)
5-point trend, -136.9%
-95.3%

주당 지표 EPS, 주당 순자산, 주당 현금 흐름, 주당 배당금

지표
5년 추세
CRL
동종업계 중앙값
EPS (Diluted) (EPS (희석))
5-point trend, -138.3%
$-2.91

자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율

지표
5년 추세
CRL
동종업계 중앙값

CRL 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력

매수 22 명의 애널리스트
  • 적극 매수 5 22.7%
  • 매수 10 45.5%
  • 보유 7 31.8%
  • 매도 0 0.0%
  • 적극 매도 0 0.0%

12개월 목표 주가

14 명의 애널리스트 · 2026-08-14
중앙값 목표 $300.00 +3.4%
평균 목표 $281.00 -3.1%

실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일

평균 서프라이즈
0.21%
기간 EPS Actual EPS 예상 서프라이즈
2026년 6월 30일 $3.02 $2.76 0.26%
2026년 3월 31일 $2.06 $1.96 0.10%
2025년 12월 31일 $2.39 $2.37 0.02%
2025년 9월 30일 $2.43 $2.36 0.07%
2025년 6월 30일 $3.12 $2.52 0.60%
2025년 3월 31일 $2.34 $2.10 0.24%

동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업

티커 시가총액 P/E 매출 YoY 순이익률 ROE 매출 총이익률
CRL $10.02B -70.0 -0.85% -3.6% -4.4%
ILMN $20.65B 24.8 -0.66% 19.6% 34.1% 66.1%
MTD $28.38B 33.2 4.0% 21.6% -615.5% 59.4%
WST $19.81B 40.5 6.2% 16.1% 16.2% 35.9%
MEDP $15.93B 36.8 20.0% 17.8% 142.9%
TEM -41.9 83.4% -19.3% -61.2%
RVTY $10.86B 46.7 3.7% 8.5% 3.3%
TECH $7.97B 111.8 5.2% 6.0% 3.7% 64.8%
TEM -41.9 83.4% -19.3% -61.2%
RGEN $9.23B 190.5 16.4% 6.6% 2.4%
BIO

전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름

손익계산서 15
CRL의 연간 손익계산서 데이터
지표 추세 202520242023202220212020201920182017201620152014
Revenue 12-point trend, +209.4% $4.02B $4.05B $4.13B $3.98B $3.54B $2.92B $2.62B $2.27B $1.86B $1.68B $1.36B $1.30B
Cost of Revenue 4-point trend, +8.7% · · · · · · · · $290M $277M $264M $266M
SG&A Expense 12-point trend, +176.2% $743M $751M $748M $665M $620M $529M $518M $444M $371M $365M $300M $269M
Operating Income 12-point trend, -85.8% $25M $227M $617M $651M $590M $433M $351M $331M $288M $238M $206M $178M
Interest Expense 10-point trend, +1044.0% · · $137M $59M $74M $86M $61M $64M $30M $28M $15M $12M
Interest Income 12-point trend, +328.1% $5M $9M $5M $780.0K $652.0K $834.0K $2M $812.0K $690.0K $1M $1M $1M
Other Non-op 12-point trend, -310.6% $-23M $-17M $96M $31M $-36M $100M $12M $13M $38M $12M $3M $11M
Pretax Income 12-point trend, -156.0% $-100M $93M $581M $623M $481M $447M $304M $282M $297M $223M $195M $178M
Income Tax 12-point trend, -10.5% $43M $68M $101M $130M $82M $82M $50M $54M $171M $67M $43M $48M
Net Income 12-point trend, -213.9% $-144M $22M $475M $486M $391M $364M $252M $226M $123M $155M $149M $127M
EPS (Basic) 12-point trend, -207.0% $-2.91 $0.20 $9.27 $9.57 $7.77 $7.35 $5.17 $4.72 $2.60 $3.29 $3.21 $2.72
EPS (Diluted) 12-point trend, -209.4% $-2.91 $0.20 $9.22 $9.48 $7.60 $7.20 $5.07 $4.62 $2.54 $3.23 $3.13 $2.66
Shares (Basic) 12-point trend, +6.3% 49,564,000 51,380,000 51,227,000 50,812,000 50,293,000 49,550,000 48,730,000 47,947,000 47,481,000 47,014,000 46,496,000 46,627,000
Shares (Diluted) 12-point trend, +4.2% 49,564,000 51,628,000 51,451,000 51,301,000 51,425,000 50,611,000 49,693,000 49,018,000 48,564,000 47,958,000 47,634,000 47,558,000
EBITDA 12-point trend, +56.3% $428M $589M $931M $955M $855M $668M $549M $493M $419M $364M $301M $274M
대차대조표 30
CRL의 연간 대차대조표 데이터
지표 추세 202520242023202220212020201920182017201620152014
Cash & Equivalents 12-point trend, +33.6% $214M $195M $277M $234M $241M $228M $238M $195M $164M $118M $118M $160M
Short-term Investments 7-point trend, -94.8% · · · · $1M $1M $941.0K $885.0K $28M $4M $21M ·
Receivables 12-point trend, +174.8% $709M $721M $780M $752M $643M $618M $514M $472M $430M $364M $270M $258M
Inventory 12-point trend, +235.9% $299M $279M $380M $256M $199M $186M $161M $128M $115M $96M $94M $89M
Prepaid Expense 12-point trend, +185.3% $129M $106M $83M $108M $97M $73M $56M $49M $81M $45M $47M $45M
Other Current Assets 7-point trend, -100.0% · · · · · $0 $300.0K $300.0K $0 $45M $47M $73M
Current Assets 12-point trend, +149.8% $1.45B $1.40B $1.61B $1.44B $1.27B $1.20B $1.02B $898M $827M $657M $559M $579M
PP&E (Net) 12-point trend, +144.6% $1.66B $1.60B $1.64B $1.47B $1.29B $1.12B $1.04B $933M $782M $756M $678M $677M
PP&E (Gross) 12-point trend, +139.7% $3.19B $3.06B $2.98B $2.63B $2.39B $2.21B $2.02B $1.81B $1.58B $1.46B $1.32B $1.33B
Accum. Depreciation 12-point trend, +134.8% $1.54B $1.45B $1.34B $1.16B $1.10B $1.09B $978M $874M $801M $706M $645M $655M
Goodwill 12-point trend, +760.9% $2.76B $2.85B $3.10B $2.85B $2.71B $1.81B $1.54B $1.25B $805M $788M $439M $321M
Intangibles 12-point trend, +21.1% $340M $723M $864M $955M $1.06B $788M $689M $611M $370M $394M $281M $281M
Other Non-current Assets 12-point trend, +301.9% $293M $278M $309M $148M $152M $353M $213M $144M $124M $88M $72M $73M
Total Assets 12-point trend, +281.5% $7.14B $7.53B $8.20B $7.60B $7.02B $5.49B $4.69B $3.86B $2.93B $2.71B $2.07B $1.87B
Accounts Payable 12-point trend, +340.0% $149M $140M $169M $206M $198M $122M $111M $66M $78M $68M $37M $34M
Accrued Liabilities 12-point trend, +300.8% $270M $232M $228M $220M $229M $150M $139M $107M $90M $84M $89M $67M
Current Liabilities 12-point trend, +280.2% $1.12B $994M $1.06B $1.09B $1.03B $840M $710M $558M $464M $430M $312M $295M
Capital Leases 7-point trend, +273.4% $434M $484M $419M $390M $253M $156M $116M · · · · ·
Deferred Tax 12-point trend, +312.4% $95M $107M $191M $216M $240M $217M $167M $144M $90M $56M $48M $23M
Other Non-current Liabilities 12-point trend, +38.9% $138M $195M $223M $175M $243M $205M $183M $179M $195M $159M $89M $100M
Total Liabilities 12-point trend, +236.5% $3.92B $4.02B $4.54B $4.58B $4.43B $3.35B $3.03B $2.52B $1.87B $1.86B $1.30B $1.17B
Long-term Debt 5-point trend, +124.7% · · · · · · · $1.61B $1.09B $1.18B $814M $717M
Total Debt 12-point trend, -100.0% $166.0K $155.0K $3M $1M $101.0K $47M $36M $1.65B $1.12B $1.21B $836M $754M
Common Stock 12-point trend, -41.8% $492.0K $511.0K $513.0K $509.0K $505.0K $498.0K $489.0K $482.0K $875.0K $863.0K $855.0K $845.0K
Retained Earnings 12-point trend, +1100.6% $1.39B $1.81B $1.89B $1.43B $981M $625M $280M $42M $289M $165M $11M $-139M
Treasury Stock 12-point trend, -100.0% $0 $0 $0 $0 $0 $0 $0 $55.0K $1.66B $1.55B $1.54B $1.42B
AOCI 12-point trend, -131.4% $-172M $-317M $-196M $-262M $-165M $-139M $-178M $-173M $-145M $-254M $-136M $-74M
Stockholders' Equity 12-point trend, +370.8% $3.16B $3.46B $3.60B $2.98B $2.53B $2.11B $1.63B $1.32B $1.05B $837M $733M $672M
Liabilities + Equity 12-point trend, +281.5% $7.14B $7.53B $8.20B $7.60B $7.02B $5.49B $4.69B $3.86B $2.93B $2.71B $2.07B $1.87B
Shares Outstanding 12-point trend, +4.0% 49,217,000 51,141,000 51,338,000 50,944,000 50,480,000 49,767,000 48,936,000 48,209,000 47,402,000 47,363,000 46,698,000 47,327,000
현금 흐름 18
CRL의 연간 현금 흐름 데이터
지표 추세 202520242023202220212020201920182017201620152014
D&A 12-point trend, +318.2% $403M $362M $314M $304M $266M $235M $198M $162M $131M $127M $95M $96M
Stock-based Comp 12-point trend, +129.0% $71M $70M $72M $74M $71M $56M $57M $47M $44M $44M $40M $31M
Deferred Tax 12-point trend, -953.7% $-75M $-67M $-51M $-33M $-20M $2M $-21M $-10M $28M $3M $4M $9M
Amort. of Intangibles 12-point trend, +589.9% $179M $138M $137M $147M $125M $112M $90M $65M $41M $42M $24M $26M
Restructuring 12-point trend, +1181.0% $100M $107M $30M $8M $7M $13M $14M $10M $5M $18M $8M $8M
Other Non-cash 11-point trend, +122367.8% $483M $348M $-126M $-211M $53M $-111M $-5M $16M $-8M $-28M $-395.0K ·
Operating Cash Flow 12-point trend, +192.6% $738M $735M $684M $620M $761M $547M $481M $441M $318M $317M $307M $252M
CapEx 12-point trend, +285.0% $219M $233M $319M $325M $229M $167M $141M $140M $82M $55M $63M $57M
Investing Cash Flow 10-point trend, +69.8% $-209M $-245M $-563M $-608M $-1.44B $-602M $-682M $-955M $-73M $-693M · ·
Debt Issued 10-point trend, +17.5% $1.23B $1.08B $776M $2.95B $6.95B $2.23B $3.36B $2.76B $237M $1.04B · ·
Net Debt Issued 8-point trend, -55.4% $1.23B $1.08B $776M $2.95B $6.95B $2.23B $3.36B $2.76B · · · ·
Stock Repurchased 12-point trend, +195.6% $361M $119M $24M $39M $41M $24M $18M $14M $107M $12M $117M $122M
Net Stock Activity 12-point trend, -195.6% $-361M $-119M $-24M $-39M $-41M $-24M $-18M $-14M $-107M $-12M $-117M $-122M
Financing Cash Flow 10-point trend, -241.0% $-537M $-551M $-86M $-42M $673M $47M $232M $558M $-208M $381M · ·
Net Change in Cash 12-point trend, +154.6% $10M $-79M $43M $-5M $13M $-7M $43M $31M $46M $-69.0K $-43M $4M
Taxes Paid 8-point trend, +77.0% $120M $126M $90M $76M $75M $60M $54M $68M · · · ·
Free Cash Flow 12-point trend, +165.6% $518M $502M $365M $295M $532M $380M $340M $301M $236M $245M $225M $195M
Levered FCF 10-point trend, +35.4% · · $252M $248M $471M $309M $290M $250M $223M $226M $213M $186M
수익성 7
CRL의 연간 수익성 데이터
지표 추세 202520242023202220212020201920182017201620152014
Operating Margin 12-point trend, -95.4% 0.63% 5.6% 14.9% 16.4% 16.7% 14.8% 13.4% 14.6% 15.5% 14.1% 15.1% 13.7%
Net Margin 11-point trend, -132.8% -3.6% 0.55% 11.5% 12.2% 11.0% 12.5% 9.6% 10.0% 6.6% 9.2% 10.9% ·
Pretax Margin 12-point trend, -118.1% -2.5% 2.3% 14.1% 15.7% 13.6% 15.3% 11.6% 12.4% 16.0% 13.3% 14.3% 13.7%
EBITDA Margin 12-point trend, -49.5% 10.7% 14.5% 22.6% 24.0% 24.2% 22.8% 20.9% 21.8% 22.5% 21.6% 22.1% 21.1%
ROA 11-point trend, -126.0% -2.0% 0.28% 6.0% 6.7% 6.2% 7.1% 5.9% 6.7% 4.4% 6.5% 7.6% ·
ROE 11-point trend, -120.5% -4.4% 0.63% 14.4% 17.6% 16.8% 19.4% 17.1% 19.2% 13.1% 19.7% 21.2% ·
ROIC 12-point trend, -87.5% 1.1% 1.8% 14.2% 17.3% 19.3% 16.4% 17.6% 9.0% 5.6% 8.1% 10.2% 9.1%
유동성 및 지급능력 5
CRL의 연간 유동성 및 지급능력 데이터
지표 추세 202520242023202220212020201920182017201620152014
Current Ratio 12-point trend, -37.0% 1.3 1.4 1.5 1.3 1.2 1.4 1.4 1.6 1.8 1.5 1.8 2.0
Quick Ratio 12-point trend, -41.7% 0.8 0.9 1.0 0.9 0.9 1.0 1.1 1.2 1.3 1.1 1.2 1.4
Debt / Equity 12-point trend, -100.0% 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 1.1 1.4 1.1 1.1
LT Debt / Equity 5-point trend, +15.0% · · · · · · · 1.2 1.0 1.4 1.1 1.1
Interest Coverage 10-point trend, -69.6% · · 4.5 11.0 8.0 5.0 5.8 5.2 9.7 8.6 13.7 14.9
효율성 3
CRL의 연간 효율성 데이터
지표 추세 202520242023202220212020201920182017201620152014
Asset Turnover 12-point trend, -25.8% 0.5 0.5 0.5 0.5 0.6 0.6 0.6 0.7 0.7 0.7 0.7 0.7
Inventory Turnover 4-point trend, -8.0% · · · · · · · · 2.7 2.9 2.9 3.0
Receivables Turnover 12-point trend, +3.6% 5.6 5.4 5.4 5.7 5.6 5.2 5.3 5.0 4.7 5.3 5.2 5.4
주당 5
CRL의 연간 주당 데이터
지표 추세 202520242023202220212020201920182017201620152014
Book Value / Share 12-point trend, +352.7% $64.30 $67.69 $70.06 $58.42 $50.21 $42.49 $33.40 $27.33 $22.05 $17.67 $15.70 $14.20
Revenue / Share 10-point trend, +131.1% $81.01 $78.45 $80.26 $77.50 $68.84 $57.77 $52.75 $46.23 $38.25 $35.06 · ·
Cash Flow / Share 10-point trend, +137.6% $14.88 $14.23 $13.29 $12.08 $14.79 $10.80 $9.68 $9.00 $6.55 $6.26 · ·
Cash / Share 12-point trend, +28.5% $4.34 $3.81 $5.39 $4.59 $4.78 $4.59 $4.86 $4.05 $3.46 $2.48 $2.53 $3.38
EPS (TTM) 12-point trend, -209.4% $-2.91 $0.20 $9.22 $9.48 $7.60 $7.20 $5.07 $4.62 $2.54 $3.23 $3.13 $2.66
성장률 7
CRL의 연간 성장률 데이터
지표 추세 202520242023202220212020201920182017201620152014
Revenue YoY 5-point trend, -104.0% -0.85% -1.9% 3.9% 12.3% 21.1% · · · · · · ·
Revenue CAGR 3Y 3-point trend, -97.3% 0.33% 4.6% 12.2% · · · · · · · · ·
Revenue CAGR 5Y 6.6% · · · · · · · · · · ·
EPS YoY 4-point trend, -1859.5% · -97.8% -2.7% 24.7% 5.6% · · · · · · ·
EPS CAGR 3Y 2-point trend, -917.9% · -70.3% 8.6% · · · · · · · · ·
Net Income YoY 4-point trend, -1402.2% · -95.3% -2.4% 24.4% 7.3% · · · · · · ·
Net Income CAGR 3Y 2-point trend, -767.7% · -61.6% 9.2% · · · · · · · · ·
가치 평가 (TTM) 14
CRL의 연간 가치 평가 (TTM) 데이터
지표 추세 202520242023202220212020201920182017201620152014
Revenue TTM 12-point trend, +209.4% $4.02B $4.05B $4.13B $3.98B $3.54B $2.92B $2.62B $2.27B $1.86B $1.68B $1.36B $1.30B
Net Income TTM 12-point trend, -213.9% $-144M $22M $475M $486M $391M $364M $252M $226M $123M $155M $149M $127M
Market Cap 12-point trend, +229.4% $10.02B $9.52B $12.14B $11.10B $18.64B $12.53B $7.43B $5.39B $5.19B $3.61B $3.74B $3.04B
Enterprise Value 12-point trend, +169.8% $9.81B $9.33B $11.86B $10.87B $18.40B $12.34B $7.23B $6.84B $6.12B $4.70B $4.46B $3.64B
P/E 12-point trend, -389.6% -70.0 930.8 25.6 23.0 48.6 35.0 30.0 24.2 43.1 23.6 25.6 24.2
P/S 12-point trend, +6.5% 2.5 2.4 2.9 2.8 5.3 4.3 2.8 2.4 2.8 2.1 2.7 2.3
P/B 12-point trend, -30.0% 3.2 2.8 3.4 3.7 7.4 5.9 4.5 4.1 5.0 4.3 5.1 4.5
P / Tangible Book 166.0 · · · · · · · · · · ·
P / Cash Flow 12-point trend, +12.6% 13.6 13.0 17.7 17.9 24.5 22.9 15.5 12.2 16.3 12.0 13.0 12.1
P / FCF 12-point trend, +24.0% 19.3 19.0 33.2 37.6 35.0 33.0 21.8 17.9 22.0 14.7 16.6 15.6
EV / EBITDA 12-point trend, +72.6% 22.9 15.8 12.7 11.4 21.5 18.5 13.2 13.9 14.6 12.9 14.8 13.3
EV / FCF 12-point trend, +1.6% 18.9 18.6 32.5 36.9 34.6 32.5 21.2 22.7 26.0 19.2 19.8 18.6
EV / Revenue 12-point trend, -12.8% 2.4 2.3 2.9 2.7 5.2 4.2 2.8 3.0 3.3 2.8 3.3 2.8
Earnings Yield 12-point trend, -134.5% -1.4% 0.11% 3.9% 4.3% 2.1% 2.9% 3.3% 4.1% 2.3% 4.2% 3.9% 4.1%

재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년

손익계산서
2025-12-272024-12-282023-12-302022-12-312021-12-25
매출 $4.02B$4.05B$4.13B$3.98B$3.54B
영업이익률 % 0.63%5.6%14.9%16.4%16.7%
순이익 $-144M$22M$475M$486M$391M
희석 EPS $-2.91$0.20$9.22$9.48$7.60
대차대조표
2025-12-272024-12-282023-12-302022-12-312021-12-25
부채 / 자기자본 비율 0.00.00.00.00.0
유동비율 1.31.41.51.31.2
당좌 비율 0.80.91.00.90.9
현금 흐름
2025-12-272024-12-282023-12-302022-12-312021-12-25
잉여현금흐름 $518M$502M$365M$295M$532M

최신 뉴스 이 회사 관련 최근 헤드라인

나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목

📊

중요한 지표를 선택하세요 — 위 전체 기본 재무제표의 아무 행 옆에 있는 ➕를 클릭하세요.

선택 항목이 저장되어 모든 티커에서 유지됩니다.

기관 투자자 (13F) 617개의 제출자 · $7.8B 전체 · 기준일 2026년 6월 30일

분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.

기관 활동 — Q2 2026 대 이전 분기
신규 포지션 청산 포지션 증가함 감소 순주식 변동
82 (-8 이전 분기 대비) 61 (-20 이전 분기 대비) 180 (-11 이전 분기 대비) 201 (+13 이전 분기 대비) -972K

Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.

기관 가치 주식 % 추적된 13F 중 유형
FMR LLC $737,350,307 3,251,247 9.42% 주식
VANGUARD CAPITAL MANAGEMENT LLC $714,227,026 3,149,288 9.12% 주식
HARRIS ASSOCIATES L P $508,269,048 2,241,144 6.49% 주식
VANGUARD PORTFOLIO MANAGEMENT LLC $501,427,927 2,210,979 6.40% 주식
STATE STREET CORP $422,800,968 1,864,284 5.40% 주식
DIMENSIONAL FUND ADVISORS LP $348,883,077 1,538,354 4.46% 주식
CITADEL ADVISORS LLC $270,696,771 1,193,601 3.46% 주식
GEODE CAPITAL MANAGEMENT, LLC $259,130,041 1,144,937 3.31% 주식
EARNEST PARTNERS LLC $254,007,295 1,120,011 3.24% 주식
WELLINGTON MANAGEMENT GROUP LLP $223,361,616 984,883 2.85% 주식
AMERIPRISE FINANCIAL INC $192,886,814 850,503 2.46% 주식
NEUBERGER BERMAN GROUP LLC $192,182,793 847,488 2.45% 주식
Clearbridge Investments, LLC $177,185,527 781,276 2.26% 주식
COOKE & BIELER LP $171,369,328 755,630 2.19% 주식
VICTORY CAPITAL MANAGEMENT INC $150,762,735 664,768 1.93% 주식
MILLENNIUM MANAGEMENT LLC $110,324,717 486,462 1.41% 주식
BANK OF AMERICA CORP /DE/ $104,921,899 462,639 1.34% 주식
Gotham Asset Management, LLC $98,233,181 433,146 1.25% 주식
Amundi $93,528,650 412,402 1.19% 주식
NORGES BANK $83,921,372 370,040 1.07% 주식
MARSHALL WACE, LLP $76,947,125 339,288 0.98% 주식
Iron Triangle Partners LP $75,748,141 379,728 0.97% 주식
ALLIANCEBERNSTEIN L.P. $64,615,913 374,585 0.83% 주식
SNYDER CAPITAL MANAGEMENT L P $63,899,443 281,756 0.82% 주식
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP $63,174,169 278,558 0.81% 주식
BNP PARIBAS FINANCIAL MARKETS $63,095,473 278,211 0.81% 주식
VANGUARD FIDUCIARY TRUST CO $61,384,115 270,665 0.78% 주식
PRIMECAP MANAGEMENT CO/CA/ $60,523,448 266,870 0.77% 주식
GOLDMAN SACHS GROUP INC $57,319,812 252,744 0.73% 주식
Meridiem Capital Partners LP $56,012,367 246,979 0.72% 주식
Alyeska Investment Group, L.P. $53,295,650 235,000 0.68% 주식
Quantinno Capital Management LP $49,020,824 216,150 0.63% 주식
ADAGE CAPITAL PARTNERS GP, L.L.C. $48,415,129 213,480 0.62% 주식
Boston Trust Walden Corp $46,506,918 205,066 0.59% 주식
Burgundy Asset Management Ltd. $45,453,909 278,329 0.58% 주식
SRS Investment Management, LLC $42,496,817 187,384 0.54% 주식
LOOMIS SAYLES & CO L P $38,517,487 169,838 0.49% 주식
JONES FINANCIAL COMPANIES LLLP $37,184,513 172,350 0.47% 주식
PERCEPTIVE ADVISORS LLC $31,750,600 140,000 0.41% 주식
LAKEWOOD CAPITAL MANAGEMENT, LP $30,389,860 134,000 0.39% 주식
NEW YORK STATE COMMON RETIREMENT FUND $29,879,583 131,750 0.38% 주식
BlackRock, Inc. $29,025,945 127,986 0.37% 주식
PICTON MAHONEY ASSET MANAGEMENT $26,340,305 116,144 0.34% 주식
FIL Ltd $25,184,576 111,048 0.32% 주식
Candriam S.C.A. $23,824,478 105,152 0.30% 주식
Clark Capital Management Group, Inc. $23,010,567 101,462 0.29% 주식
Vanguard Global Advisers, LLC $22,453,344 99,005 0.29% 주식
Swiss National Bank $22,452,210 99,000 0.29% 주식
CONFLUENCE INVESTMENT MANAGEMENT LLC $20,491,384 90,354 0.26% 주식
ENVESTNET ASSET MANAGEMENT INC $20,280,546 89,424 0.26% 주식
SUSQUEHANNA INTERNATIONAL GROUP, LLP $19,730,730 87,000 0.25% 콜 옵션
NOMURA HOLDINGS INC $19,672,672 86,744 0.25% 주식
RHUMBLINE ADVISERS $19,484,825 85,916 0.25% 주식
Ilex Capital Partners (UK) LLP $18,413,760 81,193 0.24% 주식
Aristotle Capital Boston, LLC $18,273,438 80,574 0.23% 주식
CITADEL ADVISORS LLC $17,485,509 77,100 0.22% 콜 옵션
NICHOLAS COMPANY, INC. $16,305,067 71,895 0.21% 주식
MANUFACTURERS LIFE INSURANCE COMPANY, THE $15,172,024 66,899 0.19% 주식
Mitsubishi UFJ Asset Management Co., Ltd. $15,164,087 66,864 0.19% 주식
Ranger Investment Management, L.P. $15,009,416 66,182 0.19% 주식
California Public Employees Retirement System $14,670,818 64,689 0.19% 주식
Assenagon Asset Management S.A. $14,020,385 61,821 0.18% 주식
ASSETMARK, INC $13,939,194 61,463 0.18% 주식
Rhenman & Partners Asset Management AB $12,972,388 57,200 0.17% 주식
RIVERBRIDGE PARTNERS LLC $12,859,587 56,703 0.16% 주식
TD Asset Management Inc $12,854,230 56,679 0.16% 주식
SUSQUEHANNA INTERNATIONAL GROUP, LLP $12,836,314 56,600 0.16% 풋 옵션
Laurus Investment Counsel Inc. $12,365,663 71,685 0.16% 주식
KING LUTHER CAPITAL MANAGEMENT CORP $12,204,023 53,812 0.16% 주식
FRONTIER CAPITAL MANAGEMENT CO LLC $11,552,133 50,938 0.15% 주식
Universal- Beteiligungs- und Servicegesellschaft mbH $10,732,081 47,278 0.14% 주식
RAYMOND JAMES FINANCIAL INC $10,506,727 46,328 0.13% 주식
VANGUARD ASSET MANAGEMENT, Ltd $10,472,482 46,177 0.13% 주식
KENNEDY CAPITAL MANAGEMENT LLC $9,914,950 43,719 0.13% 주식
BARCLAYS PLC $9,909,816 43,696 0.13% 주식
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM $9,827,670 56,972 0.13% 주식
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM $9,382,529 41,371 0.12% 주식
Park West Asset Management LLC $9,343,748 41,200 0.12% 주식
State of Tennessee, Department of Treasury $8,457,000 37,290 0.11% 주식
J.P. Marvel Investment Advisors, LLC $8,456,092 37,286 0.11% 주식
CASTLEARK MANAGEMENT LLC $8,174,646 36,045 0.10% 주식
JANE STREET GROUP, LLC $7,869,613 34,700 0.10% 콜 옵션
Pine Ridge Advisers LLC $7,710,860 34,000 0.10% 주식
PRUDENTIAL FINANCIAL INC $7,346,635 32,394 0.09% 주식
Capricorn Fund Managers Ltd $7,092,630 31,274 0.09% 주식
STATE OF WISCONSIN INVESTMENT BOARD $7,000,554 30,868 0.09% 주식
FIRST TRUST ADVISORS LP $6,951,290 30,651 0.09% 주식
Caption Management, LLC $6,803,700 30,000 0.09% 풋 옵션
Engineers Gate Manager LP $6,637,463 29,267 0.08% 주식
LAWSON KROEKER INVESTMENT MANAGEMENT INC/NE $6,351,027 28,004 0.08% 주식
Midwest Trust Co $6,091,126 26,858 0.08% 주식
VAN ECK ASSOCIATES CORP $5,942,578 26,203 0.08% 주식
SEI INVESTMENTS CO $5,929,630 26,150 0.08% 주식
Sendero Wealth Management, LLC $5,909,468 26,057 0.08% 주식
13D Management LLC $5,851,182 25,800 0.07% 주식
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $5,500,853 31,889 0.07% 주식
D. E. Shaw & Co., Inc. $5,462,691 24,087 0.07% 주식
INVESTMENT HOUSE LLC $5,447,042 24,018 0.07% 주식
LPL Financial LLC $5,409,169 23,851 0.07% 주식
LRT Capital Management, LLC $5,348,842 23,585 0.07% 주식

회사 내부자 57 명의 내부자 · 21 임원 · 27 이사

내부자 역할 마지막 활동 보유 주식 수 매수 12개월 매도 12개월 순매수/매도 12개월
Glenn Coleman EVP & Chief Financial Officer 2026년 5월 29일 A 27,752 0 0 $0
Flavia Pease Corporate Executive VP & CFO 2025년 5월 31일 F 17,297 0 0 $0
David Ross Smith Corporate Executive VP & CFO 2022년 3월 3일 M 25,819 0 0 $0
Davide Molho President & COO 2018년 7월 24일 M 17,155 0 0 $0
Mark Mintz EVP, Chief Information Officer 2026년 5월 31일 F 9,546 0 0 $0
William D Barbo Corporate Executive VP & CCO 2024년 11월 7일 G 23,337 0 0 $0
John W Kuo CEVP General Counsel & CCO 2020년 6월 1일 A 3,171 0 0 $0
David P Johst Corporate Executive VP 2020년 5월 29일 A 224,478 0 0 $0
John J Crowley SVP, Chief Accounting Officer 2016년 10월 1일 F 5,599 0 0 $0
Nancy Gillett Corporate Executive VP 2016년 3월 2일 S 11,034 0 0 $0
Jorg Geller Corporate Executive VP 2015년 2월 25일 M 14,094 0 0 $0
RENAUD REAL H Corp. Executive VP 2010년 8월 11일 F 74,390 0 0 $0
Christopher Berthoux Executive Vice President 2010년 2월 26일 A 31,897 0 0 $0
Joanne P Acford Corp. Sr VP, GC and Corp. Sec 2007년 8월 11일 F 37,109 0 0 $0
David J Elliott Officer 2007년 6월 29일 M 11,750 0 0 $0
Cheri L Walker Corporate Senior VP 2007년 5월 1일 A 6,262 0 0 $0
Stephanie B Wells Senior Vice President 2007년 4월 2일 A 11,500 0 0 $0
Nicholas Ventresca Senior Vice President 2007년 4월 2일 F 12,713 0 0 $0
John C Ho Senior Vice President 2007년 2월 23일 A 12,710 0 0 $0
Brian Bathgate Corporate Vice President 2006년 2월 27일 S 16,134 0 0 $0
Alastair Stuart Mcewan Corporate VP 2004년 12월 23일 M 8,000 0 0 $0
Steven Barg 이사 2026년 6월 2일 A 3,287 0 0 $0
Nancy C Andrews 이사 2026년 5월 12일 G 3,964 0 0 $0
Reshema Kemps-Polanco 이사 2026년 5월 8일 A 4,563 0 0 $0
George Llado 이사 2026년 5월 8일 A 6,702 0 0 $0
Abraham Ceesay 이사 2026년 5월 8일 A 2,384 0 0 $0
Mark J Enyedy 이사 2026년 5월 8일 A 2,384 0 0 $0
Paul W Graves 이사 2026년 5월 8일 A 2,384 0 0 $0
Craig B. Thompson 이사 2026년 5월 8일 A 3,851 0 0 $0
Martin Mackay 이사 2026년 5월 8일 A 17,137 0 0 $0
Virginia M Wilson 이사 2026년 5월 8일 A 6,349 0 0 $0
George Massaro 이사 2025년 5월 15일 S 5,575 0 0 $0
Richard F Wallman 이사 2024년 11월 7일 S 0 0 0 $0
Deborah Turner Kochevar 이사 2024년 5월 13일 A 7,894 0 0 $0
Robert J Bertolini 이사 2024년 5월 13일 A 32,802 0 0 $0
Richard C Reese 이사 2023년 5월 15일 A 65,541 0 0 $0
George M Milne JR 이사 2021년 5월 7일 A 29,079 0 0 $0
Stephen D Chubb 이사 2021년 2월 23일 M 40,529 0 0 $0
Jean-Paul Mangeolle 이사 2019년 5월 22일 A 3,886 0 0 $0
William Waltrip 이사 2012년 12월 5일 S 21,830 0 0 $0
Samuel O Thier MD 이사 2012년 5월 9일 A 18,230 0 0 $0
Douglas E Rogers 이사 2010년 5월 7일 A 12,859 0 0 $0
Nancy T Chang 이사 2010년 5월 7일 A 31,010 0 0 $0
Linda Mcgoldrick 이사 2006년 2월 13일 A 0 0 $0
Walter S Nimmo 이사 2005년 2월 25일 S 149,447 0 0 $0
John Urquhart 이사 2005년 2월 17일 A 11,738 0 0 $0
Louise S Mccrary 이사 2005년 2월 17일 A 0 0 $0
Robert Cawthorn 이사 2004년 6월 2일 G 278,600 0 0 $0
Shannon M Parisotto 2026년 8월 11일 M 4,807 0 2 $-2,365,755
Birgit Girshick 2026년 8월 11일 M 36,013 0 1 $-1,819,350

SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당

행동주의자 및 5% 이상 소유자 6 보유

SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.

제출자 제출됨 지분 상태 목적 제출
JANA PARTNERS LLC ×4 제출 서류 2011년 8월 4일 최초 제출 SEC
Relational Investors, LLC, Relational Investors Mid-Cap Fund I, L.P., Relational Investors Mid-Cap Fund II, L.P., Ralph V. Whitworth, David H. Batchelder, California State Teachers’ Retirement System ×3 제출 서류 2011년 2월 9일 최초 제출 SEC
Neuberger Berman Group LLC, Neuberger Berman LLC, Neuberger Berman Management ×3 제출 서류 2010년 12월 7일 최초 제출 SEC
미공개 보고자 2010년 6월 16일 최초 제출 SEC
미공개 보고자 2010년 6월 7일 최초 제출 수동적 투자 SEC
Charles River Laboratories International, Inc. IRS No. 061397316 2010년 5월 5일 최초 제출 이사회 캠페인 SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

ETF 보유 현황 134 ETF 보유

가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.

펀드 비중 단위 기준일 출처
HTEC · EXCHANGE TRADED CONCEPTS TRUST 1.49% 4,749 NS 2026년 4월 30일 N-PORT
EPSB · Harbor ETF Trust 1.33% 370 NS 2026년 4월 30일 N-PORT
EPMV · Harbor ETF Trust 1.09% 291 NS 2026년 4월 30일 N-PORT
EPSV · Harbor ETF Trust 0.90% 270 NS 2026년 4월 30일 N-PORT
TAX · EA Series Trust 0.80% 1,131 NS 2026년 5월 29일 N-PORT
LSEQ · Harbor ETF Trust 0.66% 612 NS 2026년 4월 30일 N-PORT
HIBL · Direxion Shares ETF Trust 0.50% 2,356 NS 2026년 4월 30일 N-PORT
FNY · First Trust Exchange-Traded AlphaDE… 0.38% 11,925 NS 2026년 4월 30일 N-PORT
IQSM · New York Life Investments ETF Trust 0.33% 6,161 NS 2026년 4월 30일 N-PORT
FFSM · FIDELITY COVINGTON TRUST 0.29% 22,440 NS 2026년 4월 30일 N-PORT
DFAT · Dimensional ETF Trust 0.26% 212,321 NS 2026년 4월 30일 N-PORT
BKMC · BNY Mellon ETF Trust 0.22% 8,115 NS 2026년 4월 30일 N-PORT
FSMD · FIDELITY COVINGTON TRUST 0.17% 24,528 NS 2026년 4월 30일 N-PORT
SCHM · SCHWAB STRATEGIC TRUST 0.17% 133,341 NS 2026년 5월 31일 N-PORT
DFAS · Dimensional ETF Trust 0.16% 138,243 NS 2026년 4월 30일 N-PORT
BBMC · J.P. Morgan Exchange-Traded Fund Tr… 0.15% 18,369 NS 2026년 4월 30일 N-PORT
MSSM · MORGAN STANLEY PATHWAY FUNDS 0.15% 6,079 NS 2026년 5월 31일 N-PORT
FHLC · FIDELITY COVINGTON TRUST 0.13% 22,674 NS 2026년 4월 30일 N-PORT
DFSV · Dimensional ETF Trust 0.13% 59,338 NS 2026년 4월 30일 N-PORT
RXL · ProShares Trust 0.13% 513 NS 2026년 5월 31일 N-PORT
REVS · Columbia ETF Trust I 0.12% 2,082 NS 2026년 4월 30일 N-PORT
CURE · Direxion Shares ETF Trust 0.12% 982 NS 2026년 4월 30일 N-PORT
FAD · First Trust Exchange-Traded AlphaDE… 0.11% 3,280 NS 2026년 4월 30일 N-PORT
FBCV · FIDELITY COVINGTON TRUST 0.11% 1,032 NS 2026년 4월 30일 N-PORT
AVMC · AMERICAN CENTURY ETF TRUST 0.09% 1,986 NS 2026년 5월 31일 N-PORT
FNX · First Trust Exchange-Traded AlphaDE… 0.07% 5,261 NS 2026년 4월 30일 N-PORT
RECS · Columbia ETF Trust I 0.06% 20,810 NS 2026년 4월 30일 N-PORT
DXUV · Dimensional ETF Trust 0.06% 1,328 NS 2026년 4월 30일 N-PORT
SPXD · DBX ETF Trust 0.05% 19 NS 2026년 5월 31일 N-PORT
DFUV · Dimensional ETF Trust 0.05% 41,210 NS 2026년 4월 30일 N-PORT
DFAC · Dimensional ETF Trust 0.04% 105,382 NS 2026년 4월 30일 N-PORT
DCOR · Dimensional ETF Trust 0.03% 5,627 NS 2026년 4월 30일 N-PORT
SCHV · SCHWAB STRATEGIC TRUST 0.03% 24,676 NS 2026년 5월 31일 N-PORT
GVUS · Goldman Sachs ETF Trust 0.03% 591 NS 2026년 5월 31일 N-PORT
SNPE · DBX ETF Trust 0.02% 3,759 NS 2026년 5월 29일 N-PORT
EGLE · Global X Funds 0.02% 3 NS 2026년 4월 30일 N-PORT
CHRI · Global X Funds 0.02% 7 NS 2026년 4월 30일 N-PORT
DEUS · DBX ETF Trust 0.02% 337 NS 2026년 5월 29일 N-PORT
SPXT · ProShares Trust 0.02% 328 NS 2026년 5월 31일 N-PORT
FNDX · SCHWAB STRATEGIC TRUST 0.02% 30,460 NS 2026년 5월 31일 N-PORT
QRFT · Exchange Listed Funds Trust 0.02% 19 NS 2026년 4월 30일 N-PORT
FNDB · SCHWAB STRATEGIC TRUST 0.02% 1,472 NS 2026년 5월 31일 N-PORT
SPUS · Tidal Trust I 0.02% 3,014 NS 2026년 5월 31일 N-PORT
DFSU · Dimensional ETF Trust 0.02% 2,431 NS 2026년 4월 30일 N-PORT
DFAU · Dimensional ETF Trust 0.02% 10,974 NS 2026년 4월 30일 N-PORT
SPXN · ProShares Trust 0.02% 69 NS 2026년 5월 31일 N-PORT
JUST · Goldman Sachs ETF Trust 0.01% 455 NS 2026년 5월 31일 N-PORT
SPXE · ProShares Trust 0.01% 67 NS 2026년 5월 31일 N-PORT
DSPY · Tema ETF Trust 0.01% 697 NS 2026년 5월 31일 N-PORT
XRMI · Global X Funds 0.01% 41 NS 2026년 4월 30일 N-PORT